Biological Agents for Psoriasis Management in HIV-Positive Patients: A Literature Review
This article is part of Special Issue:
Miaoqi Qiu,
Bo Feng,
Chengyao Zhu,
Lunfei Liu,
Miaoqi Qiu
Department of Dermatology , The Fourth Affiliated Hospital , Zhejiang University School of Medicine , Yiwu , 322000 , China , zju.edu.cn
International Institutes of Medicine , Zhejiang University School of Medicine , Yiwu , 322000 , China , zju.edu.cn
Search for more papers by this authorBo Feng
Department of Dermatology , The Fourth Affiliated Hospital , Zhejiang University School of Medicine , Yiwu , 322000 , China , zju.edu.cn
Search for more papers by this authorChengyao Zhu
Department of Dermatology , The Fourth Affiliated Hospital , Zhejiang University School of Medicine , Yiwu , 322000 , China , zju.edu.cn
Search for more papers by this authorCorresponding Author
Lunfei Liu
Department of Dermatology , The Fourth Affiliated Hospital , Zhejiang University School of Medicine , Yiwu , 322000 , China , zju.edu.cn
Search for more papers by this authorMiaoqi Qiu,
Bo Feng,
Chengyao Zhu,
Lunfei Liu,
Miaoqi Qiu
Department of Dermatology , The Fourth Affiliated Hospital , Zhejiang University School of Medicine , Yiwu , 322000 , China , zju.edu.cn
International Institutes of Medicine , Zhejiang University School of Medicine , Yiwu , 322000 , China , zju.edu.cn
Search for more papers by this authorBo Feng
Department of Dermatology , The Fourth Affiliated Hospital , Zhejiang University School of Medicine , Yiwu , 322000 , China , zju.edu.cn
Search for more papers by this authorChengyao Zhu
Department of Dermatology , The Fourth Affiliated Hospital , Zhejiang University School of Medicine , Yiwu , 322000 , China , zju.edu.cn
Search for more papers by this authorCorresponding Author
Lunfei Liu
Department of Dermatology , The Fourth Affiliated Hospital , Zhejiang University School of Medicine , Yiwu , 322000 , China , zju.edu.cn
Search for more papers by this authorFirst published: 06 January 2025
Academic Editor: Yung-Tsu Cho
Abstract
The management of HIV-positive psoriasis patients places a heavy burden on the healthcare system, as there are no standard treatment regimens for these patients and the use of biologics has only been reported sporadically. Here, we conducted a systematic review over the past six years and identified 22 articles containing 34 patients treated with inhibitors against tumor necrosis factor alpha (TNF-α), interleukin (IL)-12/23, IL-17, or IL-23. Our analysis focuses on the effectiveness and safety profile of biological agents, highlighting IL-23 inhibitor’s superior clinical response and tolerability for plaque psoriasis in concomitant HIV-positive patients. Therefore, we suggest IL-23 inhibitor as a promising treatment option for moderate-to-severe psoriasis in HIV-positive patients.
Conflicts of Interest
The authors declare no conflicts of interest.
Open Research
Data Availability Statement
The data that support the findings of this study are openly available in [PubMed] at https://pubmed.ncbi.nlm.nih.gov/, reference number [1–48].
References
- 1 Boehncke W.-H. and Schön M. P., Psoriasis, The Lancet. (2015) 386, no. 9997, 983–994, https://doi.org/10.1016/S0140-6736(14)61909-7, 2-s2.0-84941421180.
- 2 Queirós N. and Torres T., HIV-Associated Psoriasis, Actas Dermo-Sifiliográficas. (2018) 109, no. 4, 303–311, https://doi.org/10.1016/j.ad.2017.09.014, 2-s2.0-85044636528.
- 3 Fink D. L., Hedley L., and Miller R. F., Systematic Review of the Efficacy and Safety of Biological Therapy for Inflammatory Conditions in HIV-Infected Individuals, International Journal of STD & AIDS. (2017) 28, no. 2, 110–119, https://doi.org/10.1177/0956462416675109, 2-s2.0-85011599919.
- 4 Ceccarelli M., Venanzi Rullo E., Vaccaro M. et al., HIV-Associated Psoriasis: Epidemiology, Pathogenesis, and Management, Dermatologic Therapy. (2019) 32, no. 2, https://doi.org/10.1111/dth.12806, 2-s2.0-85059585372.
- 5 Myers B., Thibodeaux Q., Reddy V. et al., Biologic Treatment of 4 HIV-Positive Patients: A Case Series and Literature Review, Journal of Psoriasis and Psoriatic Arthritis. (2021) 6, no. 1, 19–26, https://doi.org/10.1177/2475530320954279.
- 6
Agarwal A.,
Panda M., and
Ray A., Complete Remission of Psoriatic Erythroderma Using Modified Low Dose Etanercept in a HIV Positive Patient: A Case Report with Review of Literature, Dermatologic Therapy. (2021) 34, no. 3, https://doi.org/10.1111/dth.14922.
10.1111/dth.14922 Google Scholar
- 7 Naovarat B. S., Salazar G., Ishimori M., Williams F. M., and Reveille J. D., Biological Treatment Usage in Patients With HIV and Rheumatic Disease, 2003–2021: Long-Term Safety and Follow-Up, RMD Open. (2022) 8, no. 2, https://doi.org/10.1136/rmdopen-2022-002282.
- 8 Gordon K., Papp K., Poulin Y., Gu Y., Rozzo S., and Sasso E. H., Long-Term Efficacy and Safety of Adalimumab in Patients With Moderate to Severe Psoriasis Treated Continuously Over 3 years: Results From an Open-Label Extension Study for Patients From REVEAL, Journal of the American Academy of Dermatology. (2012) 66, no. 2, 241–251, https://doi.org/10.1016/j.jaad.2010.12.005, 2-s2.0-84855849399.
- 9 Wang D. M., Fernandez A. P., Calabrese C. M., and Calabrese L. H., Treatment of Psoriasis with Ustekinumab in a Patient With HIV-Related Kaposi Sarcoma, Clinical and Experimental Dermatology. (2019) 44, no. 1, 113–115, https://doi.org/10.1111/ced.13630, 2-s2.0-85055505434.
- 10 Muñoz L. C., Muñoz J. P., Taboada A. C., Casado A. F., and Bran E. L., Human Immunodeficiency Virus Infection in a Hepatitis B Virus-Positive Psoriasis Patient Treated With Ustekinumab, Cutis. (2020) 105, no. 2, E31–E32.
- 11 Di Lernia V., Casanova D. M., and Garlassi E., Secukinumab in an HIV-Positive Patient With Psoriasis, JDDG: Journal der Deutschen Dermatologischen Gesellschaft. (2019) 17, no. 6, 646–648, https://doi.org/10.1111/ddg.13851, 2-s2.0-85066012830.
- 12 Pangilinan M. C. G., Sermswan P., and Asawanonda P., Use of Anti-IL-17 Monoclonal Antibodies in HIV Patients With Erythrodermic Psoriasis, Case Reports in Dermatology. (2020) 12, no. 2, 132–137, https://doi.org/10.1159/000508781.
- 13 Qian F., Yan Y., Huang J. et al., Use of Ixekizumab in an HIV-Positive Patient With Psoriatic Arthritis, International Journal of STD & AIDS. (2022) 33, no. 5, 519–521, https://doi.org/10.1177/09564624221076289.
- 14
Di Lernia V.,
Casanova D. M., and
Ricci C., Brodalumab: Another Helpful Option for HIV-Positive Psoriatic Patients?, Dermatologic Therapy. (2020) 33, no. 6, https://doi.org/10.1111/dth.13895.
10.1111/dth.13895 Google Scholar
- 15 Gong J., Wu W., Qiu L. et al., Interleukin-17A Inhibitor Secukinumab Treatment in HIV-Positive Psoriasis Patient: A Case Report, Clinical, Cosmetic and Investigational Dermatology. (2022) 15, 2949–2956, https://doi.org/10.2147/CCID.S395348.
- 16 Qin H., Lu J., Yi X., Ding Y., and Shi Y., Secukinumab Treatment for a Psoriasis Patient Co-Infected With HIV and Latent Tuberculosis: A Case Report, The Journal of Dermatology. (2022) 49, no. 11, e415–e416, https://doi.org/10.1111/1346-8138.16494.
- 17
Romita P.,
Foti C.,
Calianno G., and
Chiricozzi A., Successful Treatment With Secukinumab in an HIV-Positive Psoriatic Patient After Failure of Apremilast, Dermatologic Therapy. (2022) 35, no. 8, https://doi.org/10.1111/dth.15610.
10.1111/dth.15610 Google Scholar
- 18 Bedier H., Isnard S., Thomas R., and Routy J.-P., Control of Porphyria Cutanea Tarda With Anti-IL-17 Secukinumab in a Person With Psoriasis Living with HIV, Oxford Medical Case Reports. (2023) 2023, no. 7, https://doi.org/10.1093/omcr/omad066.
- 19 Proietti I., Skroza N., Michelini S. et al., HIV Positive Patient Treated With Ixekizumab, La Clinica Terapeutica. (2022) 173, no. 3, 214–216, https://doi.org/10.7417/CT.2022.2420.
- 20 Gleason L., Hunter E., Cohen A., Suriano J., and Nikbakht N., Atezolizumab-Induced Psoriasiform Drug Eruption Successfully Treated With Ixekizumab: A Case Report and Literature Review, Dermatology Online Journal. (2023) 29, no. 1, https://doi.org/10.5070/D329160215.
- 21 Bartos G., Cline A., Beroukhim K., Burrall B. A., and Feldman S. R., Current Biological Therapies for Use in HIV-Positive Patients With Psoriasis: Case Report of Gesulkumab Used and Review, Dermatology Online Journal. (2018) 24, no. 11, https://doi.org/10.5070/D32411041999.
- 22
Rob F. and
Rozsypal H., Successful Treatment of Psoriasis With Risankizumab in an HIV Positive Patient With Sexually Transmitted Infection Comorbidities, Dermatologic Therapy. (2022) 35, no. 3, https://doi.org/10.1111/dth.15277.
10.1111/dth.15277 Google Scholar
- 23 Sanguinetti J., Suar L., Eimer L., and Busso C., Successful Treatment With Risankizumab in a Patient With Psoriasis and HIV], Medicina. (2022) 82, no. 4, 605–608.
- 24 Maliyar K., Lansang P., and Doiron P., Use of Risankizumab in Two HIV-Positive Patients With Psoriasis, JAAD Case Reports. (2023) 33, 54–55, https://doi.org/10.1016/j.jdcr.2023.01.015.
- 25 Orsini D., Maramao F. S., Gargiulo L. et al., Effectiveness and Safety of Risankizumab in HIV Patients With Psoriasis: A Case Series, International Journal of STD & AIDS. (2023) 35, no. 1, 67–70, https://doi.org/10.1177/09564624231199510.
- 26 Estevinho T., Freitas E., and Torres T., Risankizumab, a Therapeutic Alternative for Psoriasis in People Living With HIV, Journal of International Medical Research. (2024) 52, no. 3, https://doi.org/10.1177/03000605241229324.
- 27 Gallitano S. M., McDermott L., Brar K., and Lowenstein E., Use of Tumor Necrosis Factor (TNF) Inhibitors in Patients With HIV/AIDS, Journal of the American Academy of Dermatology. (2016) 74, no. 5, 974–980, https://doi.org/10.1016/j.jaad.2015.11.043, 2-s2.0-84954270938.
- 28 Xu J., Gill K., Flora A., Kozera E., and Frew J. W., The Impact of Psoriasis Biologic Therapy on HIV Viral Load and CD4+ Cell Counts in HIV-Positive Individuals: A Real-World Cohort Study, Journal of the European Academy of Dermatology and Venereology. (2023) 37, no. 8, 1659–1663, https://doi.org/10.1111/jdv.19020.
- 29 Valdez H. and Lederman M. M., Cytokines and Cytokine Therapies in HIV Infection, AIDS Clinical Review. (1997) 187–228.
- 30 Pasquereau S., Kumar A., and Herbein G., Targeting TNF and TNF Receptor Pathway in HIV-1 Infection: From Immune Activation to Viral Reservoirs, Viruses. (2017) 9, no. 4, https://doi.org/10.3390/v9040064, 2-s2.0-85017009938.
- 31 Risk of Infections Using Anti-TNF Agents in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis: A Systematic Review and Meta-Analysis, https://air.unimi.it/handle/2434/481066.
- 32 Poola S., Kratzer M., Sewell K., and Tillmann H. L., Size Matters! Anti-HBs Titer and HBV Reactivation During Anti-TNF Therapy, Digestive Diseases and Sciences. (2023) 68, no. 12, 4511–4520, https://doi.org/10.1007/s10620-023-08141-7.
- 33 Lyon S. M. and Rossman M. D., Pulmonary Tuberculosis, Microbiology Spectrum. (2017) 5, no. 1, https://doi.org/10.1128/microbiolspec.TNMI7-0032-2016, 2-s2.0-85023626985.
- 34 Herbein G. and Rien W., Tumor Necrosis Factor (TNF)-a and TNF Receptors in Viral Pathogenesis (44487).
- 35
Garcia I.,
Olleros M. L.,
Quesniaux V. F. J. et al., D. Wallach, A. Kovalenko, and M. Feldmann, Roles of Soluble and Membrane TNF and Related Ligands in Mycobacterial Infections: Effects of Selective and Non-Selective TNF Inhibitors During Infection, Advances in TNF Family Research, 2011, Springer, New York, NY, 187–201, https://doi.org/10.1007/978-1-4419-6612-4_20, 2-s2.0-79954429064.
10.1007/978-1-4419-6612-4_20 Google Scholar
- 36 Mills K. H. G., IL-17 and IL-17-Producing Cells in Protection Versus Pathology, Nature Reviews Immunology. (2023) 23, no. 1, 38–54, https://doi.org/10.1038/s41577-022-00746-9.
- 37 Valeri M. and Raffatellu M., Cytokines IL-17 and IL-22 in the Host Response to Infection, Pathogens and Disease. (2016) 74, no. 9, https://doi.org/10.1093/femspd/ftw111, 2-s2.0-85018390722.
- 38 van de Kerkhof P. C., Griffiths C. E. M., Reich K. et al., Secukinumab Long-Term Safety Experience: A Pooled Analysis of 10 Phase II and III Clinical Studies in Patients With Moderate to Severe Plaque Psoriasis, Journal of the American Academy of Dermatology. (2016) 75, no. 1, 83–98.e4, https://doi.org/10.1016/j.jaad.2016.03.024, 2-s2.0-84966680721.
- 39 Krstic A., Mojsilovic S., Jovcic G., and Bugarski D., The Potential of Interleukin-17 to Mediate Hematopoietic Response, Immunologic Research. (2012) 52, no. 1–2, 34–41, https://doi.org/10.1007/s12026-012-8276-8, 2-s2.0-84859916452.
- 40
Deng Z.,
Wang S.,
Wu C., and
Wang C., IL-17 Inhibitor-Associated Inflammatory Bowel Disease: A Study Based on Literature and Database Analysis, Frontiers in Pharmacology. (2023) 14, https://doi.org/10.3389/fphar.2023.1124628.
10.3389/fphar.2023.1124628 Google Scholar
- 41 Alzahrani J., Hussain T., Simar D. et al., Inflammatory and Immunometabolic Consequences of Gut Dysfunction in HIV: Parallels With IBD and Implications for Reservoir Persistence and Non-AIDS Comorbidities, EBioMedicine. (2019) 46, 522–531, https://doi.org/10.1016/j.ebiom.2019.07.027, 2-s2.0-85069613486.
- 42 Rendon A. and Schäkel K., Psoriasis Pathogenesis and Treatment, International Journal of Molecular Sciences. (2019) 20, no. 6, https://doi.org/10.3390/ijms20061475, 2-s2.0-85063806117.
- 43 Ruggiero A., Picone V., Martora F., Fabbrocini G., and Megna M., Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence, Clinical, Cosmetic and Investigational Dermatology. (2022) 15, 1649–1658, https://doi.org/10.2147/CCID.S364640.
- 44
Armstrong A. W.,
Soliman A. M.,
Betts K. A. et al., Long-Term Benefit–Risk Profiles of Treatments for Moderate-To-Severe Plaque Psoriasis: A Network Meta-Analysis, Dermatologic Therapy. (2022) 12, no. 1, 167–184, https://doi.org/10.1007/s13555-021-00647-0.
10.1007/s13555-021-00647-0 Google Scholar
- 45 Bai F., Li G. G., Liu Q., Niu X., Li R., and Ma H., Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials, Journal of Immunology Research. (2019) 2019, 1–25, https://doi.org/10.1155/2019/2546161, 2-s2.0-85072739574.
- 46 Louis S., Dutertre C.-A., Vimeux L. et al., IL-23 and IL-12p70 Production by Monocytes and Dendritic Cells in Primary HIV-1 Infection, Journal of Leukocyte Biology. (2010) 87, no. 4, 645–653, https://doi.org/10.1189/jlb.1009684, 2-s2.0-77950582718.
- 47 Garg A., Rawat P., and Spector S. A., Interleukin 23 Produced by Myeloid Dendritic Cells Contributes to T-Cell Dysfunction in HIV Type 1 Infection by Inducing SOCS1 Expression, The Journal of Infectious Diseases. (2015) 211, no. 5, 755–768, https://doi.org/10.1093/infdis/jiu523, 2-s2.0-84942342440.
- 48
Luo Z.,
Li M.,
Mi F. et al., Link Between Interleukin-23 and Anti-CD4 Autoantibody Production in Antiretroviral-Treated HIV-Infected Individuals, Journal of Virology. (2021) 95, no. 11, 002711–e321, https://doi.org/10.1128/JVI.00271-21.
10.1128/JVI.00271-21 Google Scholar
